巴曲酶联合神经节苷脂治疗急性脑梗死的临床疗效分析

目的 观察和评价巴曲酶联合神经节苷脂(GM1)治疗急性脑梗死的疗效和不良反应.方法 选择我院2011年11月至2012年11月确诊为急性脑梗死的80例患者,完全随机分为治疗组和对照组,各40例.治疗组应用神经节苷脂100 mg静脉滴注,1次/d,治疗14d,同时给予巴曲酶注射液,按10、5、5、5 BU分别于第1、3、5、7天静脉滴注一次；对照组应用GM1 100 mg静脉滴注,1次/d,同时给予奥扎格雷钠160 mg静脉滴注,1次/d,持续治疗14天.观察2组的临床疗效、神经功能缺损程度评分和血浆纤维蛋白原(Fib)的变化,并进行统计学分析.结果 治疗组显效率85.0％ (34/40)明显高于对照组60.0％ (24/40)(P＜0.05)；治疗组神经功能缺损评分(NFDS)改善明显优于对照组(12±6)比(17±6)分,P＜0.01]；2组治疗后与治疗前相比Fib含量均降低(P＜0.01),而治疗组Fib含量(1.9±0.9) g/L]相比对照组(2.3±0.7)g/L]降低的更加明显(P＜0.05).结论 巴曲酶联合GM1能有效治疗急性脑梗死,具有较好的临床疗效及安全性.

The clinical curative effect analysis of batroxobin combined with ganglioside in treatment of acute cerebral infarction

Objective To observe and evaluate batroxobin joint ganglioside treatment of patients with acute cerebral infarction of the curative effect and adverse reaction. Methods The study involved 80 patients diagnosed of acute cerebral infarction from Nov. 2011 to Nov. 2012. All the patients were randomly divided into two groups ： the treatment group and the control group. The treatment group were given ganglioside and song enzyme for 14 days. At the same time the control group were given ozagrel sodium and ganglioside for 14 days. Then we observed the clinical curative effect of the two groups, neural function defect degree score and plasma fibrinogen （Fib） change. Results Treatment group total effective rate （85.0%） was statistically higher than that in control group （60.0%） （P 〈 0.05 ） ; after treatment, the NFDS in treatment group was （12 ± 6）which was significantly better then that in control group （ 16.6 ± 6.0） （P 〈 0.01 ） ; after treatment the Fib content in treament was （ 1.86 ± 0.87） g/L which was sig- nificantly lower than that in the control group （ 2.28 ± 0.72 ） g/L （ P 〈 0.05 ）. Conclusion Two groups of combined treatment for patients with acute cerebral infarction show the good treatment effect. Song and enzyme joint ganglio- side for patients with acute cerebral infarction treatment effect are more significant than normal therapy.